Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

BELLUS Health Inc. (BLU)

9.1   -0.03 (-0.33%) 11-25 13:00
Open: 9.16 Pre. Close: 9.13
High: 9.17 Low: 9.01
Volume: 126,241 Market Cap: 1,145(M)

Technical analysis

as of: 2022-11-25 1:55:35 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 11.23     One year: 13.12
Support: Support1: 8.89    Support2: 8.44
Resistance: Resistance1: 9.61    Resistance2: 11.23
Pivot: 9.03
Moving Average: MA(5): 9.12     MA(20): 9.06
MA(100): 10.14     MA(250): 8.49
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 67.9     %D(3): 65.9
RSI: RSI(14): 46.8
52-week: High: 12.68  Low: 4.98
Average Vol(K): 3-Month: 590 (K)  10-Days: 711 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BLU ] has closed below upper band by 43.3%. Bollinger Bands are 51.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.47 - 9.52 9.52 - 9.56
Low: 8.95 - 9.02 9.02 - 9.08
Close: 9.02 - 9.13 9.13 - 9.22

Company Description

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Headline News

Sat, 26 Nov 2022
Petit Brabancon channels '70s horror in "Resonance of the corpse" live Blu-ray - JROCK NEWS

Sat, 26 Nov 2022
Blu Boys give US a scare in 1-0 loss - manilastandard.net

Fri, 25 Nov 2022
The Best Black Friday Blu-Ray Deals Under $20 - CBR - Comic Book Resources

Fri, 25 Nov 2022
Gift Guide 2022: Best of DVD and Blu-ray - Washington Times

Fri, 25 Nov 2022
Spider-Man and Venom Blu-rays Are Dirt Cheap For Black Friday 2022 - ComicBook.com

Fri, 25 Nov 2022
Star Trek Black Friday 2022 Deals Include Paramount+ For 50% Off And Blu-Rays For 50%+ Off At Amazon - TrekMovie

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 126 (M)
% Held by Insiders 9.133e+007 (%)
% Held by Institutions 9.5 (%)
Shares Short 12,600 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -454
Return on Assets (ttm) 418.7
Return on Equity (ttm) -16.8
Qtrly Rev. Growth 16000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -68 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 60509.3
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 1.141e+007
Dividend Yield 0%
Dividend Pay Date 2019-08-18
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.